Pregabalin Capsule
Product Images NDC 71610-894

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71610-894). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (71610 0894 30)

Pregabalin 100 mg capsules, bottle label for 30 capsules by Aphena Pharma Solutions - Tennessee, LLC. Label includes storage instructions, manufacturer and labeler details, NDC number 71610-894-30, and a warning that the drug may be habit forming and is prescription only.*

FDA Label Image

Aphena (Aphena)

FDA Label Image

Chemical Structure (Pregabalin 01)

Chemical structure of pregabalin, the active ingredient in the product, showing its molecular layout including carboxyl (CO2H) and amino (NH2) groups attached to a branched carbon backbone.*

FDA Label Image

Figure 1 (Pregabalin 02)

A line graph showing percent of patients improved plotted against percent improvement in pain from baseline. It compares Pregabalin at 200 mg, 100 mg, 25 mg three times a day, and a placebo, indicating treatment efficacy in pain improvement.*

FDA Label Image

Figure 2 (Pregabalin 03)

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline. The graph includes two curves: one for Pregabalin 100 mg taken three times a day and one for placebo, showing higher improvement rates in the Pregabalin group across the range of pain improvement percentages.*

FDA Label Image

Figure 3 (Pregabalin 04)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline. The graph compares four groups: Pregabalin 300 mg twice daily, Pregabalin 150 mg twice daily, Pregabalin 75 mg twice daily, and placebo. The x-axis shows percent improvement in pain from baseline, and the y-axis shows the percent of patients improved.*

FDA Label Image

Figure 4 (Pregabalin 05)

A line chart showing percent of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, showing trends in patient improvement across different pain reduction percentages.*

FDA Label Image

Figure 5 (Pregabalin 06)

A line graph showing percent of patients improved versus percent improvement in pain from baseline, comparing Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo groups. The graph illustrates patient improvement distributions at various pain improvement thresholds.*

FDA Label Image

Figure 6 (Pregabalin 07)

A bar chart comparing responder rates (%) across different dosages of Pregabalin and placebo in two studies, Study E1 and Study E3. The X-axis shows placebo and Pregabalin doses (150 mg/day to 600 mg/day), while the Y-axis represents responder rates from 0% to 60%. Data include sample sizes and statistical significance versus placebo indicated by asterisk.*

FDA Label Image

Figure 7 (Pregabalin 08)

This is a line chart depicting seizure reduction as median percentage change from baseline versus dose (mg/day) for Pregabalin. The chart compares results from multiple studies (E1 BD, E2 TID, E3 BD, E3 TID) with markers indicating different dosing schedules, along with p-values showing statistical significance.*

FDA Label Image

Figure 8 (Pregabalin 09)

A bar graph depicting responder rates (%) for three groups: placebo, 2.5 mg/kg/day, and 10 mg/kg/day. The responder rate increases from 22.6% for placebo (n=93) to 29.1% for 2.5 mg/kg/day (n=103) and 40.6% for 10 mg/kg/day (n=96). The vertical axis is labeled 'Responder Rate (%)' with values from 0 to 60.*

FDA Label Image

Figure 9 (Pregabalin 10)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at daily doses of 600 mg, 450 mg, 300 mg, and placebo. The graph compares outcomes across different dosing groups with lines representing each treatment group.*

FDA Label Image

Figure 10 (Pregabalin 11)

A survival curve chart depicting the estimated percentage of subjects without LTR over a period of 180 days. Two lines compare Pregabalin and placebo groups, with the Pregabalin group showing a higher percentage of subjects without LTR over time.*

FDA Label Image

Figure 11 (Pregabalin 12)

A line graph comparing the percent of subjects improved over time, from baseline to Week 12, between Pregabalin and Placebo groups. The x-axis shows percent improved, while the y-axis shows the percent of subjects improved. The Pregabalin group has a higher improvement curve compared to Placebo.*

FDA Label Image

Figure 12 (Pregabalin 13)

A line graph comparing the percentage of subjects improved over a range of improvement percentages from baseline to Week 16 BOCF, with separate lines for Pregabalin and Placebo. The vertical axis shows the percent of subjects improved, while the horizontal axis shows the percent improved from baseline to Week 16. The solid line represents Pregabalin, and the dashed line represents Placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.